+64.4%
INTU vs MRNA
+794.5%
-730.1%
-68.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.4% | -4.8% | +2.5% | -2.1% |
| 7D | -8.6% | -20.9% | +12.3% | -7.4% |
| 30D | -3.8% | -13.3% | +9.5% | -3.3% |
| 3M | -10.2% | +212.6% | -222.8% | -20.2% |
| 6M | -21.6% | +309.0% | -330.6% | -32.5% |
| YTD | -52.0% | +567.3% | -619.4% | -61.0% |
| 1Y | -51.1% | +689.7% | -740.8% | -61.0% |
| 3Y | -42.6% | +157.4% | -200.0% | -51.0% |
| 5Y | -48.2% | -21.7% | -26.4% | -52.2% |
| All | +64.4% | +794.5% | -730.1% | +30.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling